Verona Pharma reports strong Q1 2025 financial results with significant growth from Ohtuvayre sales

From GlobeNewswire: 2025-04-29 06:00:00

Verona Pharma reports total net revenue of $76.3 million for Q1 2025, with Ohtuvayre® net sales contributing $71.3 million (+95% vs Q4 2024). Approximately 25,000 prescriptions were filled in Q1 2025, exceeding operating expenses. A conference call will be held today at 9:00 a.m. EDT / 2:00 p.m. BST.

The strong US launch of Ohtuvayre for COPD led to significant growth in prescriptions and new patients. Verona plans to add 30 sales representatives to accelerate the launch. Q1 2025 performance metrics include over 25,000 prescriptions filled, 5,300 prescribers, and refills representing 60% of dispenses.

Verona Pharma’s near-term milestones include a Phase 2b trial for a fixed-dose combination of ensifentrine and glycopyrrolate for COPD, regulatory activities in the EU and UK, and Nuance Pharma’s Phase 3 trial results in Greater China. The Company’s financial results showed net revenue of $76.3 million, with operating expenses and key financial metrics detailed.

Adjusted Net Income for Q1 2025 was $20.5 million, reflecting the Company’s long-term profitability trends. The non-GAAP financial measure excludes share-based compensation and provides additional insight into Verona’s operating performance. A reconciliation of Adjusted Net Income to Net loss is provided for clarity.

Verona Pharma encourages patients to be aware of Ohtuvayre’s important safety information, including potential side effects and contraindications. The Company’s focus on developing innovative therapies for chronic respiratory diseases underscores its commitment to improving patient outcomes and addressing unmet medical needs.



Read more at GlobeNewswire:: Verona Pharma Reports First Quarter 2025 Financial Results